Aim: To find out outcome following single intravitreal injection of ranibizumab in central retinal vein occlusion (CRVO) patients in a government hospital in the capital of Odisha. Methods: This study was a prospective interventional study of 18 months duration done from August 2017 to February 2019 included 15 cases of CRVO. Thorough history was taken and detail ophthalmological evaluation was done. Best corrected visual acuity (BCVA) was examined with Snellen's chart and central macular thickness (CMT) was measured using optical coherence tomography (OCT). Routine blood tests were done. Intravitreal injection of ranibizumab 0.5 mg in 0.05 ml was given. BCVA and CMT was measured at 1 day, 1 week, 1 month and 3 month follow up visit. Results: Mean age was 59.53 ± 8.65 years. Male: female ratio was 2.8:1. Diastolic blood pressure of ≥ 90 was found in 46.7% patients. 60% cases showed improvement at 1 week post-operatively.At post-operative day 1 CMT was significantly decreased (p= 0.0193). Reduction in mean CMT at post-operative day 7 was >290 µ. Conclusion: Single intravitreal injection of ranibizumab 0.5 mg in 0.05 ml causes significant increase in vision and significant reduction of central macular thickness in patients with branch retinal vein occlusion.
Introduction
The central retinal vein and artery possesses a common sheath at crossing points posterior to the lamina cribrosa so that atherosclerotic changes of the artery may precipitate CRVO. 1 Hematological prothrombic factors may also amplify the effects of an atherosclerotic predisposition. After venous occlusion, elevation of venous and capillary pressure with stagnation of blood flow ensues, resulting in retinal hypoxia that leads to damage to the capillary endothelial cells, extravasation of blood constituents and liberation of blood mediators such as VEGF. Systemic risk factors associated with RVO include hypertension, http://jmscr.igmpublication.org/home/ ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i7.52 diabetes mellitus, cerebrovascular disease, cardiovascular disease, increased body mass index, reduced high-density lipoprotein cholesterol levels, smoking, thyroid disorder, and peptic ulcer. 2 Ocular risk factors associated with RVO include glaucoma or ocular hypertension, shorter axial length, and focal arteriolar narrowing and arteriovenous (AV) nicking. 3 CRVO can be divided into 2 types: -Nonischaemic CRVO and ischaemic CRVO. Nonischaemic CRVO is called as venous stasis retinopathy and is more common than ischaemic CRVO. 4 Around a third will progress to ischaemic CRVO within months. Macular edema is common, but mild in these cases. Other names for ischemic central retinal vein occlusion include complete, nonperfused, or hemorrhagic retinopathy. 5 Central retinal vein occlusion is one of the main causes of sudden, painless vision loss in adults. 6 Ischamic CRVO is characterized by substantially decreased retinal perfusion with capillary closure and retinal hypoxia.Findings typically show marked retinal edema, venous dilation, and extensive 4-quadrant haemorrhage. 7 Macular ischaemia and neovascular glaucoma (NVG) are the major causes of visual morbidity. Visual acuity is usually counting finger (CF) or worse. RAPD is usually present. Hundred day glaucoma may occur. Central macular edema is present in all cases. Central macular thickness (CMT) of >250 µ requires treatment. Intravitreal anti-VEGF agents or dexamethasone may be used. Ranibizumab is a humanized, VEGF antibody fragment that neutralizes all isoforms of VEGF-A.Intravitreal injection of ranibizumab 0.5 mg in 0.05 ml may be given in CRVO. In this study the effects of single dose intravitreal injection of ranibizumab 0.5 mg in 0.05 ml in CRVO patients were evaluated.
Methods
This study was a prospective interventional study of 18 months duration done from August 2017 to February 2019 in a government run hospital in the capital of Odisha included 15 cases of CRVO. Detailed history was taken in patients attending retina out patients department (OPD). Visual acuity was measured using Snellen's chart. Anterior segment examination was done with slit lamp. Posterior segment examination was done with indirect ophthalmoscope and slit lamp biomicroscope with +90 D lens. Optical coherence tomography (OCT) was done to measure macular thickness. Patients having CRVO were included in the study. They were admitted and routine blood tests were done. Fasting blood sugar, post prandial blood sugar, HbA1C, serum urea, serum creatinine, lipid profile tests were checked. Thorough cardiovascular checkup was done in all patients. In the operation theatre under all aseptic conditions intravitreal injection of ranibizumab 0.5 mg in 0.05 ml provided free of cost by state government was given under topical anaesthesia in all patients. Visual acuity and macular thickness were examined at post-op day 1. Follow up examinations were done at the end of 1 week, 1 month and 3 month. 11(73.3%) patients were male and 4 (26.7%) patients were female. Male: female ratio was 2.8:1. In 9 (60%) cases right eye was involved and in 6 cases (40%) left eye was involved. In most of the patients fasting blood sugar was within normal limit with mean FBS = 95.47 ± 24.57. Systolic blood pressure of ≥ 150 was found in 4 (26.7%) patients and diastolic blood pressure of ≥ 90 was found in 7 (46.7%) patients. 4 (26.7%) patients had HbA1C > 6.5% with mean= 6.33 ± 0.005 %.
In 5 (33.3%) patients LDL level was > 100 mg/dl. Table 2 shows the pre-operative and postoperative best corrected visual acuity (BCVA). Figure 1 shows the fundus photograph of a CRVO patient. Figure 2 shows the OCT images of retina at presentation and each follow up after giving intravitreal injection of ranibizumab. 
Discussion
In 8 The mean central macular thickness at baseline was 887 μ and decreased to a mean of 372 μ at month 1 (P < 0.001) after giving intravitreal bevacizumab. 8 Iturralde et al in their study found the mean central macular thickness at baseline was 887 µ and decreased to a mean of 372 µ at month 1 (P < 0.001) after giving intravitreal bevacizumab. 8 Brown et al in a study found CMT had decreased by a mean of 452 μ (0.5 mg) in the ranibizumab groups after 6 month. 9 At day 7, mean reduction from baseline CFT was >250 μ after injection. 9 In our study mean CMT decreased by >290 μ after 7 days of giving operation. At the end of 3 month decrease in mean CMT was >380 μ.
Conclusion
Single intravitreal injection of ranibizumab 0.5 mg causes significant increase in vision and significant reduction of central macular thickness in patients with central retinal vein occlusion.
